Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Dare Bioscience (DARE) Amortization of Deferred Charges (2016 - 2025)

Dare Bioscience's Amortization of Deferred Charges history spans 7 years, with the latest figure at $124251.0 for Q3 2025.

For Q3 2025, Amortization of Deferred Charges changed N/A year-over-year to $124251.0; the TTM value through Sep 2025 reached $135873.0, up 150.08%, while the annual FY2017 figure was $316805.0, 24.57% down from the prior year.
Amortization of Deferred Charges reached $124251.0 in Q3 2025 per DARE's latest filing, up from -$5910.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $124251.0 in Q3 2025 to a low of -$5910.0 in Q2 2025.